We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod

Lutz Achtnichts, MD1; Otilia Obreja, MD, PhD1; Anna Conen, MD2; Christoph A. Fux, MD2; Krassen Nedeltchev, MD1
[+] Author Affiliations
1Department of Neurology, Cantonal Hospital of Aarau, Aarau, Switzerland
2Department of Infectious Diseases, Cantonal Hospital of Aarau, Aarau, Switzerland
JAMA Neurol. 2015;72(10):1203-1205. doi:10.1001/jamaneurol.2015.1746.
Text Size: A A A
Published online


This case report discusses a man with relapsing-remitting multiple sclerosis taking fingolimod who presented with throbbing bilateral, retro-orbital and temporal headache, photophobia, and lethargy.

Fingolimod, the first oral drug approved for relapsing-remitting multiple sclerosis (MS), acts primarily by blocking the outlet of lymphocytes from the lymph nodes.1 Despite the resulting lymphocytopenia, the overall incidences of infections with fingolimod were similar to those in the control groups of the pivotal studies.2 Nevertheless, since the drug’s approval in 2010, few cases of serious infections have emerged under fingolimod treatment.3

Figures in this Article

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Magnetic Resonance Imaging (MRI) Findings on Repeated Examinations

A, On day 2, axial T2-weighted MRI shows multiple nonenhancing supratentorial and infratentorial (not shown) lesions (arrowheads). B, On day 8, new T2-weighted MRI lesions in the basal ganglia, again without gadolinium enhancement (arrowheads). Similar lesions were also identified in the pons and the mesencephalon (not shown). C, On day 28, gadolinium enhancement in the basal ganglia on T1-weighted MRI (arrowheads).

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections